candesartan has been researched along with arachidonic acid in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
Abe, K; Abe, M; Arima, S; Endo, Y; Ito, S; Ogawa, S; Omata, K; Takeuchi, K; Tsunoda, K; Yaoita, H | 1 |
Hoagland, KM; Ito, O; Ito, S; Omata, K; Roman, RJ | 1 |
Hu, G; Ito, O; Kohzuki, M; Miura, T; Muroya, Y; Ogawa, Y; Rong, R; Wang, W | 1 |
4 other study(ies) available for candesartan and arachidonic acid
Article | Year |
---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arachidonic Acid; Arterioles; Benzimidazoles; Biphenyl Compounds; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Endothelium, Vascular; Humans; Imidazoles; In Vitro Techniques; Kidney Glomerulus; Large-Conductance Calcium-Activated Potassium Channels; Male; Norepinephrine; Perfusion; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Calcium-Activated; Pyridines; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetraethylammonium; Tetrazoles; Vasoconstrictor Agents; Vasodilator Agents | 1997 |
Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arachidonic Acid; Benzimidazoles; Biphenyl Compounds; Bradykinin; Bradykinin Receptor Antagonists; Captopril; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Desoxycorticosterone; Enalapril; Enzyme Inhibitors; Hydroxyeicosatetraenoic Acids; Kidney; Kidney Cortex; Kidney Medulla; Male; Microsomes; Mixed Function Oxygenases; NADPH-Ferrihemoprotein Reductase; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Spironolactone; Tetrazoles | 2001 |
Angiotensin II upregulates CYP4A isoform expression in the rat kidney through angiotensin II type 1 receptor.
Topics: Angiotensin II; Animals; Arachidonic Acid; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cytochrome P-450 CYP4A; Disease Models, Animal; Gene Expression Regulation; Humans; Hydroxyeicosatetraenoic Acids; Hypertension; Kidney; Protein Isoforms; Rats; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles | 2018 |